[
  {
    "ts": "2025-10-06T20:05:00+00:00",
    "headline": "Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales",
    "summary": "LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), known as Merck in the U.S. and Canada, through a wholly owned subsidiary or a nominee, today announced that the High Court of Justice of England and Wales has approved the",
    "url": "https://finance.yahoo.com/news/acquisition-verona-msd-approved-high-200500598.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "34256b1e-4985-35ee-aeae-318e03e9a9e9",
      "content": {
        "id": "34256b1e-4985-35ee-aeae-318e03e9a9e9",
        "contentType": "STORY",
        "title": "Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales",
        "description": "",
        "summary": "LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), known as Merck in the U.S. and Canada, through a wholly owned subsidiary or a nominee, today announced that the High Court of Justice of England and Wales has approved the",
        "pubDate": "2025-10-06T20:05:00Z",
        "displayTime": "2025-10-06T20:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/7a37880ab415a7f66acc4aa9a219cd8f",
          "originalWidth": 1200,
          "originalHeight": 581,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jvCClcfc5izSfRoLPpDOsA--~B/aD01ODE7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/7a37880ab415a7f66acc4aa9a219cd8f.cf.webp",
              "width": 1200,
              "height": 581,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8Lz14L0qcODqCKa7w7OS5A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7a37880ab415a7f66acc4aa9a219cd8f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/acquisition-verona-msd-approved-high-200500598.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/acquisition-verona-msd-approved-high-200500598.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRNA"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-06T15:33:00+00:00",
    "headline": "Biotech Stocks Are Up. The Sector Is Looking Better Than It Has in Years.",
    "summary": "The  SPDR S&P Biotech  exchange-traded fund, which tracks a broad selection of biotech names, has shot up 8.9% since September 25, just more than a week ago.  The biotech run-up over the past week or so has been fueled by the same drug-pricing deal between  Pfizer  and President Donald Trump that set off a surge in Big Pharma share prices last Tuesday, along with a spate of acquisitions.  “Investors are naturally jittery, since prior rallies haven’t been sustained,” Cantor Fitzgerald analysts Josh Schimmer and Eric Schmidt wrote in a note on Friday.",
    "url": "https://www.barrons.com/articles/biotech-stocks-sector-7ce04668?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "3df188b8-25cf-3d84-9780-7466e2499d15",
      "content": {
        "id": "3df188b8-25cf-3d84-9780-7466e2499d15",
        "contentType": "STORY",
        "title": "Biotech Stocks Are Up. The Sector Is Looking Better Than It Has in Years.",
        "description": "",
        "summary": "The  SPDR S&P Biotech  exchange-traded fund, which tracks a broad selection of biotech names, has shot up 8.9% since September 25, just more than a week ago.  The biotech run-up over the past week or so has been fueled by the same drug-pricing deal between  Pfizer  and President Donald Trump that set off a surge in Big Pharma share prices last Tuesday, along with a spate of acquisitions.  “Investors are naturally jittery, since prior rallies haven’t been sustained,” Cantor Fitzgerald analysts Josh Schimmer and Eric Schmidt wrote in a note on Friday.",
        "pubDate": "2025-10-06T15:33:00Z",
        "displayTime": "2025-10-06T15:33:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/3df188b8-25cf-3d84-9780-7466e2499d15/biotech-stocks-are-up-the.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/5b87ae5eee5e23955039c71dcae4a3e8",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pASWUiuvqY1FXySUWh2LUg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/5b87ae5eee5e23955039c71dcae4a3e8.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WRNl25CBcq2JoP9AvcdBCg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/5b87ae5eee5e23955039c71dcae4a3e8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/biotech-stocks-sector-7ce04668?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "XBI"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-06T13:03:00+00:00",
    "headline": "Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk",
    "summary": "Zacks Value Trader weighs whether big pharma names like Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk are genuine bargains or value traps.",
    "url": "https://finance.yahoo.com/news/zacks-value-trader-highlights-pfizer-130300884.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "6d08f1a8-176a-3ade-a598-575c20dab7b1",
      "content": {
        "id": "6d08f1a8-176a-3ade-a598-575c20dab7b1",
        "contentType": "STORY",
        "title": "Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk",
        "description": "",
        "summary": "Zacks Value Trader weighs whether big pharma names like Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk are genuine bargains or value traps.",
        "pubDate": "2025-10-06T13:03:00Z",
        "displayTime": "2025-10-06T13:03:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YqcOBKMNrThKvJSga1KIbw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_Vj9Bix098SQE5mY9G0P2w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/zacks-value-trader-highlights-pfizer-130300884.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zacks-value-trader-highlights-pfizer-130300884.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-06T12:12:09+00:00",
    "headline": "Assessing Merck Shares After Research Center Cuts and 13.5% Weekly Price Surge",
    "summary": "Trying to decide what to do with Merck’s stock right now? You are definitely not alone. After all, just in the past week, Merck’s shares have jumped 13.5%, a rapid turnaround when you consider the stock is still down 10.1% for the year and has dropped 14.8% over the past twelve months. The recent spike stands out after a long period of underperformance, catching the attention of investors looking for signals of a comeback or signs of shifting risk. What is driving this renewed momentum? A lot...",
    "url": "https://finance.yahoo.com/news/assessing-merck-shares-research-center-121209332.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "ee8be936-def0-3cda-8fe7-677bf95662dd",
      "content": {
        "id": "ee8be936-def0-3cda-8fe7-677bf95662dd",
        "contentType": "STORY",
        "title": "Assessing Merck Shares After Research Center Cuts and 13.5% Weekly Price Surge",
        "description": "",
        "summary": "Trying to decide what to do with Merck’s stock right now? You are definitely not alone. After all, just in the past week, Merck’s shares have jumped 13.5%, a rapid turnaround when you consider the stock is still down 10.1% for the year and has dropped 14.8% over the past twelve months. The recent spike stands out after a long period of underperformance, catching the attention of investors looking for signals of a comeback or signs of shifting risk. What is driving this renewed momentum? A lot...",
        "pubDate": "2025-10-06T12:12:09Z",
        "displayTime": "2025-10-06T12:12:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/assessing-merck-shares-research-center-121209332.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/assessing-merck-shares-research-center-121209332.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-06T10:45:00+00:00",
    "headline": "Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases",
    "summary": "RAHWAY, N.J., October 06, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced it has initiated three Phase 2b trials evaluating the safety and efficacy of tulisokibart (MK-7240), an investigational humanized monoclonal antibody targeting tumor necrosis factor (TNF)-like cytokine 1A (TL1A), in patients with three immune-mediated inflammatory diseases:",
    "url": "https://finance.yahoo.com/news/merck-expands-tulisokibart-clinical-development-104500324.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "db9c6e37-b03d-3dbf-9818-5657f3ecd69e",
      "content": {
        "id": "db9c6e37-b03d-3dbf-9818-5657f3ecd69e",
        "contentType": "STORY",
        "title": "Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases",
        "description": "",
        "summary": "RAHWAY, N.J., October 06, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced it has initiated three Phase 2b trials evaluating the safety and efficacy of tulisokibart (MK-7240), an investigational humanized monoclonal antibody targeting tumor necrosis factor (TNF)-like cytokine 1A (TL1A), in patients with three immune-mediated inflammatory diseases:",
        "pubDate": "2025-10-06T10:45:00Z",
        "displayTime": "2025-10-06T10:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/454109653137b16299fad4ea56918d40",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ejBJ1Y4Ml5QTSxKCh_gCqg--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/454109653137b16299fad4ea56918d40.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jr1.Ww1Z5HSGrgVWPpT3gw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/454109653137b16299fad4ea56918d40.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-expands-tulisokibart-clinical-development-104500324.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-expands-tulisokibart-clinical-development-104500324.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]